Last reviewed · How we verify

stavudine, efavirenz, lamivudine

Bristol-Myers Squibb · Phase 3 active Small molecule

stavudine, efavirenz, lamivudine is a Antiretroviral combination therapy (NRTI/NNRTI) Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for HIV-1 infection.

This is a fixed-dose combination of three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by inhibiting reverse transcriptase.

This is a fixed-dose combination of three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by inhibiting reverse transcriptase. Used for HIV-1 infection.

At a glance

Generic namestavudine, efavirenz, lamivudine
SponsorBristol-Myers Squibb
Drug classAntiretroviral combination therapy (NRTI/NNRTI)
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhasePhase 3

Mechanism of action

Stavudine and lamivudine are NRTIs that compete with natural nucleotides and cause chain termination during HIV reverse transcription. Efavirenz is an NNRTI that directly binds to and inhibits reverse transcriptase. Together, these three agents provide complementary inhibition of the enzyme essential for HIV replication, reducing viral load and slowing disease progression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about stavudine, efavirenz, lamivudine

What is stavudine, efavirenz, lamivudine?

stavudine, efavirenz, lamivudine is a Antiretroviral combination therapy (NRTI/NNRTI) drug developed by Bristol-Myers Squibb, indicated for HIV-1 infection.

How does stavudine, efavirenz, lamivudine work?

This is a fixed-dose combination of three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by inhibiting reverse transcriptase.

What is stavudine, efavirenz, lamivudine used for?

stavudine, efavirenz, lamivudine is indicated for HIV-1 infection.

Who makes stavudine, efavirenz, lamivudine?

stavudine, efavirenz, lamivudine is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).

What drug class is stavudine, efavirenz, lamivudine in?

stavudine, efavirenz, lamivudine belongs to the Antiretroviral combination therapy (NRTI/NNRTI) class. See all Antiretroviral combination therapy (NRTI/NNRTI) drugs at /class/antiretroviral-combination-therapy-nrti-nnrti.

What development phase is stavudine, efavirenz, lamivudine in?

stavudine, efavirenz, lamivudine is in Phase 3.

What are the side effects of stavudine, efavirenz, lamivudine?

Common side effects of stavudine, efavirenz, lamivudine include Peripheral neuropathy, Lipodystrophy, Dizziness/CNS effects, Rash, Hepatotoxicity, Pancreatitis.

What does stavudine, efavirenz, lamivudine target?

stavudine, efavirenz, lamivudine targets HIV reverse transcriptase and is a Antiretroviral combination therapy (NRTI/NNRTI).

Related